Experience with mexidol in neurological practice

Gromova O.A.; Torshin I.Iu.; Stakhovskaya L.V.; Pepelyaev E.G.; Semenov V.A.; Nazarenko A.G.

doi:https://doi.org/10.17116/jnevro201811810197

Close metadata

Recommended articles:

The effect of Mexidol on the level of neurogenesis markers in acute cerebrovascular accident in the experiment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):107-112

Personal characteristics of patients with cerebral microangiopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):51-56

Modern approaches to diagnosis and treatment of postinfectious asthenic syndrome in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):42-52

The main mechanisms of development of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18

The known and new ideas about the mechanism of action and the spectrum of effects of Mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):22-33

Results of the international multicenter randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of the sequential therapy with ethylmethylhydroxypyridine succinate in patients in the acute and early recovery periods of ischemic stroke (MIR). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):40-53

Study of drug-drug interactions between Mexidol and thrombolytic drugs. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):139-144

Improving the quality of life and the possibility of pathogenetic therapy in adult patients with cerebral palsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):75-84

The impact of Mexidol on improving quality of life parameters and functional kidney status as part of complex therapy for cognitive impairments in comorbid patients with microalbuminuria against the background of arterial hypertension and type 2 diabetes mellitus. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(4):478-478

The possibilities of antioxidant neuroretinoprotection in the treatment of primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;(4):49-59

Abstract:

Antihypoxic, antioxidant and nootropic effects of mexidol contribute to the improvement of patients with cerebrovascular pathology. The results of clinical studies show that the sequential scheme of using mexidol (first i.v. or i.m., then per os) is effective in the complex therapy of ischemic diseases of the brain, vascular surgery, therapy and rehabilitation of patients with degenerative-dystrophic changes of the spine, treatment of neurodegenerative pathology (including multiple sclerosis, Parkinson’s disease and diabetic polyneuropathy), infectious neuropathies (ARVI, herpes, tick-borne encephalitis), neuropsychological and autonomic disorders.

Keywords:

neurotransmission

GABA

acetylcholine

antihypoxants

nootropics

data mining

mexidol

Authors:

Gromova O.A.

Rossiĭskiĭ satellitnyĭ tsentr instituta mikroélementov IuNESKO;
Laboratoriia vychislitel'noĭ i sistemnoĭ biologii VTs RAN im. A.A. Dorodnitsyna;
kafedra farmakologii i klinicheskoĭ farmakologii Ivanovskoĭ gosudarstvennoĭ meditsinskoĭ akademii

ORCID: 0000-0002-7663-710X

Torshin I.Iu.

Rossiĭskiĭ satellitnyĭ tsentr instituta mikroélementov IuNESKO;
Laboratoriia vychislitel'noĭ i sistemnoĭ biologii VTs RAN im. A.A. Dorodnitsyna

Stakhovskaya L.V.

Pirogov Russian National Research Medical University, Moscow, Russia

Pepelyaev E.G.

FGBOU VO «Kemerovo State Medical University» MH RF, Kemerovo, Russia

Semenov V.A.

Kemerovskaia gosudarstvennaia meditsinskaia akademiia, Kemerovo

Nazarenko A.G.

OOO Klinika spinal'noĭ neĭrokhirurgii «Aksis»;
NII neĭrokhirurgii im. akad. N.N. Burdenko RAMN, Moskva

Close metadata

References:

Voronina TA, Smirnov LD, Dumayev KM. Influence of the membrane modulator from the class 3-oxypyridine on the pharmacological activity of psychotropic drugs. Bulletin of Experimental Biology and Medicine. 1985;99(5):519-522. (In Russ.)
Voronina TA. The role of oxidative stress and antioxidants in maladaptation of various genesis. Pharmacy and Pharmacology. 2015;3(5):8-17. (In Russ.) https://doi.org/10.19163/2307-9266-2015-3-5s
Voronina TA, Seredenin SB. Metodicheskie ukazaniya po izucheniyu trankviliziruyushchego (anksioliticheskogo) dejstviya farmakologicheskih veshchestv. Rukovodstvo po ehksperimental’nomu (doklinicheskomu) izucheniyu novyh farmakologicheskih veshchestv Minzdrav RF. M.: Remedium; 2000. (In Russ.)
Gofman AG, Kozhinova TA, Krylov EN. Primenenie antioksidantov v kachestve sredstv kupirovaniya alkogol’nogo abstinentnogo sindroma. Novye napravleniya v sozdanii lekarstvennyh sredstv. Kongress «Chelovek i lekarstvo». M. 1997. (In Russ.)
Voronina TA, Kapitsa IG, Ivanova EA. A comparative study of the effects of Mexidol and Mildronate on physical performance in an experiment. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(4):70-73. (In Russ.) https://doi.org/10.17116/jnevro201711741
Torshin IYu, Gromova OA, Sardaryan IS, Fedotova LE. A comparative chemoreactome analysis of mexidol. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(1-2):75-83. (In Russ.) https://doi.org/10.17116/jnevro20171171275-84
Seredenin SB, Blednov YuA, Gordey ML. Effect of membrane-modulator 3-oxypyridine on the emotionally stressful reaction and binding of H3 diazepam in the brain of inbred mice. Chemical and Pharmaceutical Magazine. 1987;2:134-137. (In Russ.)
Spasennikov BA. Application of Mexidol in the therapy of cerebral stroke. NovaInfo.Ru. 2017;2(58):400-416. (In Russ.)
Voronina TA. Mexidol: a spectrum of pharmacological effects. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(12):86-90. (In Russ.)
Voronina TA. The role of hypoxia in the development of stroke and convulsions. Antihypoxants. Reviews of Clinical Pharmacology and Drug Therapy. 2016;14(1):63-70. (In Russ.) https://doi.org/10.17816/RCF14163-70
Gromova OA, Torshin IYu, Kalacheva AG, Semenov VA, Rudakov KV. MexiB 6 as a result of the fortification of ethylmethylhydroxypyridine succinate with magnesium and pyridoxine: Proteome effects. Neurology, Neuropsychiatry, Psychosomatics. 2016;8(4):38-44. (In Russ.)
Deviatkina TA, Vazhnichaia EM, Oleinik NA. The regulatory effect of mexidol on the hemoglobin level under acute stress conditions. Eksp Klin Farmakol. 2007;70(5):24-26. (In Russ.)
Gonchar OA, Steshenko NN, Mankovskaya IN, Frantsuzova SB. Correction of the mitochondrial dysfunction in rat myocardium during oxidative stress caused by hypoxia. General Pathology and Pathological Physiology. 2010;5(3):44-48.
Konovalova EL, Chernomortseva ES, Pokrovsky MV, Pokrovskaya TG, Dudina EN, Lopatin DV, Denisyuk TA, Kotelnikova LV, Lesovaya Zh.S. Correction of endothelial dysfunction with a combination of l-norvaline and mexidol. Scientific bulletins of the Belgorod State University. Series: Medicine. Pharmacy. 2012;17:4-1(123):175-181. (In Russ.)
Deviatkina TA, Kovalenko EG, Smirnov LD. The effect of mexidol on the development of experimental peroxide athero-arteriosclerosis. Eksp Klin Farmakol. 1993;56(1):33-35. (In Russ.)
Loznikova SZh, Sukhodola AA, Shcharbina NIu, Shcharbin DG. Effect of magnesium, acetylsalicilic acid and emoxypine on aggregation of platelets. Biofizika. 2014;59(6):1108-1112. (In Russ.)
Vershinina AM, Gapon LI, Shurkevich NP, Bazhukhina IF, Petelina TI, Savel’eva NIu. Efficacy of emoxipin in treatment of arterial hypertension in the Far North. Klin Med (Mosk). 1999;77(12):43-46.
Kartina NP. Experience with the use of Mexidol in the treatment of hypertension in patients with dorsopathy. Bulletin of Experimental Biology and Medicine. 2012;1:146-153. (In Russ.)
Bulakhova EYu. Use of the drug «Mexidol» to optimize the treatment of hypertension in young patients. Bulletin of Experimental Biology and Medicine. 2006;1:101-103. (In Russ.)
Sheftelovich TK, Okun AM, Appakova AA. Mexidol in the complex therapy of cardiac diseases. Bulletin of Experimental Biology and Medicine. 2012;1:160-166. (In Russ.)
Aristova IV. Correction of emotional disorders in patients with arterial hypertension. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2013;113(11):88-90. (In Russ.)
Odintsova NF. Mexidol in complex therapy of arterial hypertension in elderly and senile patients. Pharmateka. 2006;20:10-20. (In Russ.)
Eremenko AA, Zyulyaeva TP, Egorov VM, Sidorenko YaV, Fominykh MV. The influence of Mexidol on the severity of the systemic inflammatory response in patients with myocardial revascularization in conditions of artificial circulation. Anesthesiology and Reanimatology. 2008;4:27-30. (In Russ.)
Gnezdilova AV, Ganshina TS, Mirzoyan RS. GABA-ergic mechanism of the cerebrovascular effect of Mexidol. Experimental and Clinical Pharmacology. 2010;73(10):11-13. (In Russ.)
Seryogin VI, Dronova TV. Application of Mexidol in intensive care for acute severe ischemic stroke. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2015;115(3-2):85-87. (In Russ.)
Odinak MM, Yanishevsky SN, Tsygan NV, Golohvastov SYu, Voznyuk IA, Trufanov AG. The use of succinates for the correction of metabolic disturbances in the ischemic penumbra zone in patients with stroke. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova (application «Insult»). 2013;12:55-60. (In Russ.)
Izhbuldina GI. Changes in the hemostasis system and free-radical lipid oxidation in the acute stage of ischemic stroke in patients on neuroprotection treatment. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(3-2):31-37. (In Russ.)
Schepankevich LA, Nikolaev YuA, Dolgova NA, Chipova DT. Optimization of lipid-containing therapy in patients with ischemic stroke and type 2 diabetes mellitus. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2016;116(2):42-45. (In Russ.)
Kovalchuk VV. Features of stroke rehabilitation. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova (application «Insult»). 2012;12:77-84. (In Russ.)
Androfagina OV, Kuznetsova TV, Svetkina AA. Mexidol in the rehabilitation of patients in the acute ischemic stroke. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2015;115(12-2):77-79. (In Russ.)
Kuznetsova EB, Salina EA, Sholomov I.I. The possibility of treatment of cognitive impairment in the complex therapy of patients with the consequences of cerebral infarction. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2015;115(11-1):103-106. (In Russ.)
Skvortsova VI, Stakhovskaya LV, Nartsyssov YaR, Bodykhov MK, Kichuck IV, Gudkova YuV, Soldatenkova TD, Kondrasheva TT, Kalinina EV, Novichkova MD, Kerbikov OB. The randomized double-blind placebo-controlled study of efficacy and safety of mexidol in the complex therapy of ischemic stroke in the acute period. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2006;106(18):47-54. (In Russ.)
Chefranova ZhYu, Makotrova TA, Udachin VA, Koledintseva EV. Efficacy of mexidol in the combination with thrombolytic therapy in patients with ischemic stroke. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(4):49-52. (In Russ.)
Kuznetsova SM, Kuznetsov VV, Yurchenko FV. Mexidol in the rehabilitation of elderly patients who underwent ischemic stroke. Pharmatec. 2009;15:111-114. (In Russ.)
Stakhovskaya LV, Shamalov NA, Khasanova DR, Melnikova EV, Agafiina AS, Golikov KV, Bogdanov EI, Yakupova AA, Roshkovskaya LV, Lukinykh LV, Lokshtanova TM, Poverennova IE, Shepankevich LA. Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA). Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(3-2):55-65. (In Russ.) https://doi.org/10.17116/jnevro20171173255-65
Gromova OA, Torshin IYu, Stelmashuk EV, Alexandrova OP, Pronin AV, Gogoleva IV, Haspekov LG. A study of the neuroprotective effect of mexidol on the cell model of glutamate stress. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;117(12):71-77. (In Russ.)
Smirnova IN, Fedorova TN, Tanashyan MM, Suslina ZA. Clinical efficacy and antioxidant activity of Mexidol in chronic cerebrovascular diseases. Atmosphere. Nervous Diseases. 2006;1:33-36. (In Russ.)
Tanashyan MM, Lagoda OV, Antonova KV. Chronic cerebrovascular diseases associated with metabolic syndrome: new treatment approaches. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(11):21-26. (In Russ.)
Chukanova EI, Chukanova AS, Mamayeva KhI. The results of the study of the efficacy and safety of mexidol in patients with chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2015;115(2-1):71-74. (In Russ.)
Gromova OA, Torshin IYu, Fedotova LE. Gerontoinformation analysis of the properties of the mexidol molecule. Neurology, Neuropsychiatry, Psychosomatics. 2017;4:46-54. (In Russ.)
Mirzoyan NR, Bagdasaryan NA, Alikhanyan KB, Meliksetyan VS, Bagdasaryan MG. Kukhtarova AM. Effect of Mexidol and hemisuccinate 2-ethyl-6-methyl-3-hydroxypyridine on lipofuscin content in rat brain tissue in conditions of local permanent ischemia. Experimental and Clinical Pharmacology. 2015;78(8):3-6. (In Russ.)
Golovkin VI, Svetlikov AV, Shapovalov AS, Popova LO. The efficacy of mexidol in carotid endarterectomy procedure in patients with cerebral atherosclerotic stenosis. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2016;116(1):51-55. (In Russ.)
Gerasimova MM. Citomediny v kompleksnoj terapii poyasnichno-krestcovyh radikulopatij. V kn.: Korteksin — pyatiletnij opyt otechestvennoj nevrologii. Pod red. Skoromca AA, D’yakonova MM. SPb.: Nauka; 2005. (In Russ.)
Putilina MV, Grishin DV. Principy korrekcii hronicheskoj ishemii golovnogo mozga u pacientov s vertebrogennoj patologiej. M.: AST345; 2013. (In Russ.)
Nechipurenko NI, Vasilevskaya LA, Griboyedova TV, Shcherbina NYu, Musienko YuI. Efficacy of mexidol in experimental cerebral ischemia. Bulletin of Experimental Biology and Medicine. 2006;1:224. (In Russ.)
Shatrova VP, Meskhi KT. Mexidol in the post-surgery rehabilitation of patients with degenerative-dystrophic diseases of the spine. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2008;108(12):68-70. (In Russ.)
Khuzhakhmetova DH. The use of Mexidol in a standardized regimen for the treatment of osteochondrosis of the spine. Bulletin of Experimental Biology and Medicine. 2012;1:219-225. (In Russ.)
Sinchenko OG. Use of antihypoxic and neurometabolic properties of Mexidol in the treatment of vertebrogenic radiculo-ischemic syndrome. Bulletin of Experimental Biology and Medicine. 2012;1:60-67. (In Russ.)
Likhacheva EB. Mexidol in the conservative treatment of lumbosacral radiculopathy. Pharmateka. 2012;6:83-87. (In Russ.)
Andreev VV. Complex treatment of spondylogenic radiculo-ischemia with the use of Mexidol. Bulletin of Experimental Biology and Medicine. 2012;1:62-68. (In Russ.)
Shatrova VP, Meskhi KT. Antioxidants in the complex treatment of vertebrogenic neurovascular syndromes. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2008;108(7):79-81. (In Russ.)
Likhacheva EB, Sholomov II. Clinical and immunological assessment of efficacy of mexidol in the treatment of lumbosacral radiculopathy. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2006;106(10):52-57. (In Russ.)
Golovkin VI. Mexidol in the complex therapy of multiple sclerosis. Bulletin of Experimental Biology and Medicine. 2012;1:24-27. (In Russ.)
Popova NF, Orlova EV, Pashchenkov MA, Boiko AN. Clinical-immunological aspects of multiple sclerosis treatment with ethylmethylhydroxypyridine succinate. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2011;111(8):53-56. (In Russ.)
Simonova YuV, Golovkin VI, Kamynin YuF. Correction of metabolic syndrome in patients with multiple sclerosis with the help of Mexidol. Bulletin of Experimental Biology and Medicine. 2006;1:82-85. (In Russ.)
Gorshkov IP, Sidorkina YV, Naumova NV. Experience with Mexidol in the treatment of patients with type 2 diabetes with diabetic polyneuropathy. Bulletin of Experimental Biology and Medicine. 2012;1:205-210. (In Russ.)
Kuznetsova EB, Sholomov II, Gerasimov SV, Salina EA. Efficiency mexidoli in patients with endocrine polyneuropathy. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2014;114(4):97-99. (In Russ.)
Makletsova MG, Rikhireva GT, Poleshchuk VV, Gryakalov KV, Timerbaeva SL, Fedorova TN. The influence of antioxidants on the formation of methemoglobin in red blood cells of patients with Parkinson’s disease in vivo and in vitro. Biomedical Chemistry. 2016;62(2):193-197. (In Russ.)
Zhulev NM, Pustozerov VG, Saikova LA, Zuev AA. The use of Mexidol in the treatment of patients with hereditary neuromuscular diseases. Bulletin of Experimental Biology and Medicine. 2006;1:22-27. (In Russ.)
Poverennova IE, Zolotovskaya IA, Bezgina EV. Diagnosis and treatment of asthenic syndrome in elderly people after acute respiratory viral infection. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2014;114(9):73-77. (In Russ.)
Mnatsakanova LI, Kusch VM. The experience of using the drug «Mexidol» in the treatment of patients with acute herpetic neuralgia of the Gasser (trigeminal) node. Bulletin of Experimental Biology and Medicine. 2006;1:58-59. (In Russ.)
Udintseva IN, Bartfelt NN, Zhukova NG, Poponina AM. Mexidol in the complex treatment of patients in the acute period of tick borne encephalitis. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(8):34-38 (In Russ.)
Antipenko E.A. Adaptogenic effects of mexidol in chronic cerebral ischemia. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;112(3):44-49. (In Russ.)
Tsaregorodtseva SA, Bondarenko MYu, Vakhraneva EV, Azin AL. Mexidol in the complex therapy of post-traumatic stress disorders. Bulletin of Experimental Biology and Medicine. 2006;1:148-151. (In Russ.)
Tepaev DV. Study of the possibility of pharmacological correction of the vegetative and immune disorders by megadol in individuals with signs of vegetative changes. Bulletin of Experimental Biology and Medicine. 2006;1:86-90. (In Russ.)
Yanishevsky SN. The experience of using the drug mexidol in the treatment of chronic cerebral circulatory insufficiency in patients with stenosing-occlusive lesion of the main brachycephalic vessels. Bulletin of Experimental Biology and Medicine. 2006;1:159-163. (In Russ.)
Medvedeva LA, Dutikova EF, Shcherbakova NE, Zagorulko OI, Gnezdilov AV, Sandrikov VA. The complex pathogenetic therapy of headache caused by the degenerative dystrophic changes of the cervical spine with signs of passive congestion. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2007;107(11):36-40. (In Russ.)
Kurbatova NA. Application of Mexidol in the complex treatment of patients with vibration disease. Bulletin of Experimental Biology and Medicine. 2012;1:187-195. (In Russ.)